NCT07446452 2026-03-03
Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
Clinical Trials
15 trialsNCT05831878 2025-11-18
RC48-ADC in HER2-low Advanced Breast Cancer
RenJi Hospital
Phase NA Recruiting
NCT05851677 2025-09-17
Disitamab Vedotin (RC48-ADC) in Breast Cancer
RenJi Hospital
Recruiting
NCT07065435 2025-07-15
RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT06540729 2025-07-08
DAB
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Recruiting
NCT06558682 2025-04-01
Neoadjuvant Therapy in Cervical Cancer
Qilu Hospital of Shandong University
Phase NA Recruiting
NCT06730373 2024-12-31
First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
Qilu Hospital of Shandong University
Phase 2 Recruiting
NCT06749860 2024-12-27
Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Recruiting
NCT06660511 2024-10-28
Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer.
Second Xiangya Hospital of Central South University
Phase EARLY_PHASE1 Recruiting
NCT06650332 2024-10-21
Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients
Zhejiang Cancer Hospital
Phase 1/2 Recruiting
NCT06560528 2024-08-19
Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT06187506 2024-07-12
Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer
Fudan University
Phase 2 Recruiting
NCT06278870 2024-02-26
Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3 Recruiting
NCT05957757 2023-08-31
RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression
RenJi Hospital
Phase 2 Recruiting
NCT05904964 2023-06-22
Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3 Recruiting